Genomic Valley Biotech share news, announcements and annual reports
BSE: 539206Pharmaceuticals & BiotechnologySmall Cap
GENOMIC VALLEY BIOTECH LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2015
Last close ₹48.10up ₹2.29 (5.00%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹45.81.
30 Oct: open ₹48.10, high ₹48.10, low ₹48.00
52-week range of traded prices to 30 Oct 2026
₹20.10Low, 29 Jan 2026₹48.10High, 30 Oct 2026
- Under BSE's graded surveillance, stage I, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15 Cr4,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.74
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −0.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 9,359
Genomic Valley Biotech routine notices
202 filed, newest first. Page 2 of 5.
Sep 2023
Aug 2023
8 Aug · Routine
Jul 2023
15 Jul · Routine
Jun 2023
29 Jun · Routine
May 2023
23 May · Routine
Apr 2023
Mar 2023
Feb 2023
Jan 2023
Dec 2022
Nov 2022
Oct 2022
Sep 2022
Jul 2022
21 Jul · Routine
Jun 2022
May 2022
31 May · Routine
Apr 2022
Mar 2022
Feb 2022
14 Feb · Routine
Jan 2022
Dec 2021
Nov 2021
15 Nov · Routine